Drugs / STA-5326
STA-5326
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00263237 | Dec 2005 → Jul 2008 | common variable immunodeficiency | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00088062 | Feb → Nov 2004 | Crohn disease | Synta Pharmaceuticals Corp. | Completed | No outcome recorded |
| Phase 24 trials · 1 missed | ||||||
| Phase 2 | NCT04446377 | Jul 2020 → Mar 2021 | COVID-19 | OrphAI Therapeutics | Completed | Missed primary |
| Phase 2 | NCT00250198 | Nov 2005 → Sep 2006 | Crohn disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 2 | NCT00234741 | Nov 2005 → ? | Crohn disease | Synta Pharmaceuticals Corp. | Completed | No outcome recorded |
| Phase 2 | NCT00138840 | Aug 2005 → ? | Crohn disease | Synta Pharmaceuticals Corp. | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT00642629 Comparator | Dec 2005 → ? | rheumatoid arthritis | Synta Pharmaceuticals Corp. | Completed | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | STA-5326 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00263237 ↗ |
| Known as | Apilimod | “METHODS: We performed a phase IIa, randomized, double-blind, placebo-controlled proof-of-concept study of apilimod, in combination with methotrexate, in 29 patients with active...” PMID 22170479 ↗ Dec 2011 |
| Known as | Apilimod Dimesylate | “LAM-002A (Apilimod Dimesylate) 125mg in five 25-mg capsules BID for 10 days” NCT04446377 ↗ |
| Known as | apilimod mesylate | “Brief report: a phase IIa, randomized, double-blind, placebo-controlled trial of apilimod mesylate, an interleukin-12/interleukin-23 inhibitor, in patients with rheumatoid arthritis.” PMID 22170479 ↗ Dec 2011 |
| Known as | LAM-002A | “LAM-002A (Apilimod Dimesylate) 125mg in five 25-mg capsules BID for 10 days” NCT04446377 ↗ |
| Known as | STA-5326 mesylate | “STA-5326 mesylate is a potential treatment for various autoimmune diseases, such as Crohn's disease, that are mediated by the inappropriate expression of Th1 cytokines.” NCT00138840 ↗ |
| Action | Inhibit | “block the release of interleukin-12” NCT00138840 ↗ |
| Route | Oral | “oral IL-12/23 Inhibitor” NCT00138840 ↗ |